Clinical Trial

DEB-TACE Prior to Liver Transplantation in the Treatment of HCC

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated October 18, 2024 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of the study is to explore whether the usage of DEB-TACE (Drug-Eluting Bead Transarterial Chemoembolization) prior to living donor liver transplantation can prolong the recurrence-free survival in patients with hepatocellular carcinoma (HCC). It is a single-center, exploratory study. The patients scheduled for living donor liver transplantation receive DEB-TACE 2 weeks prior to the surgery. The primary outcome: Recurrence-free survival (RFS) The secondary outcome:1) Overall survival (OS)；2) Pathological response rate (Pathological Response); 3) Proportion of patients completing living donor liver transplantation; 4) Adverse events related to DEB-TACE.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-04-03; most recent amendment 2024-10-16.
Status change: Not Yet Recruiting → Recruiting 2024-10-16
Trial Details
NCT Number NCT06353126
Lead Sponsor RenJi Hospital
Collaborators: Boston Scientific Corporation
Conditions Liver Cancer
Enrollment 40 participants
Start Date 2024-10-16
Primary Completion 2025-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-18